MINNEAPOLIS, Dec. 8, 2010 /PRNewswire-FirstCall/ — Uroplasty,
Inc. (Nasdaq:
UPI), a medical device company that develops, manufactures and
markets innovative proprietary products to treat voiding
dysfunctions, today announced the appointment of Mr. Robert (Rob)
Kill to its Board of Directors. Mr. Kill’s appointment
increases the membership on the Board to seven.
Mr. Kill (46) is the President, CEO and a Board member of
Virtual Radiologic Corporation, a Minneapolis-based, high growth
provider of teleradiology and technology solutions to radiology
practices and hospitals throughout the United States. Prior
to joining Virtual Radiologic, Mr. Kill served as President of the
Physicians Systems business at Misys Healthcare, a developer of
healthcare software systems. Earlier, he spent 10 years with
Baxter Healthcare, where he held senior leadership positions in
operations, marketing and sales. He holds a B.A. in Economics
from the University of Notre Dame.
“We are very pleased to have Rob join our Board at this key time
at Uroplasty,” said Patrick Maxwell, Chairman of the Board.
“His 19 years of experience with growing medical products and
service companies will be extremely valuable to us as we execute
our strategy to drive revenue growth and enhance valuation for our
shareholders.”
“I am excited to join Uroplasty’s Board as the Company
re-launches its Urgent PC Neuromodulation System in the U.S. for
the treatment of overactive bladder,” said Mr. Kill. “I
believe that my experience in a high growth environment will be of
value to Uroplasty’s Board and shareholders during this pivotal
time in the Company’s development.”
David Kaysen, President and CEO of Uroplasty said, “Rob brought
Virtual Radiologic public, growing it several fold in four years,
and then sold the company in a private transaction. As we
roll out the re
‘/>”/>
SOURCE